Population-based studies have identified several clinical variables associated with an increased risk of developing cutaneous melanoma that include phenotype, amount of and response to sun exposure, and family history. However, these observations are of limited relevance to clinical practice as the risk associated with each factor is individually modest and the characteristics of these variables lack precision when applied to a particular individual.
Objective:
To review the literature regarding recent advances made in the understanding of the genes and genetics of clinical variables associated with an increased risk of melanoma.
Conclusion:
Variants of the MC1R (melanocortin-1 receptor) have been identified as major determinants of high-risk phenotypes, such as red hair and pale skin, and the ability to tan in response to UV exposure. Several studies also suggest that such variants may increase melanoma risk independent of their contribution to phenotype. A strong genetic basis for both nevus density and size has been demonstrated and the link between nevi and the development of MM has become better defined. Finally, germline defects in several genes involved in cell cycle regulation, namely, p16 and CDK4, have been demonstrated in many familial melanoma kindreds. This progress has introduced the prospect of genetic testing as a means of identifying a limited number of high-risk individuals who can be targeted with regular screening and education regarding UV exposure and skin self-examination. Ultimately, through rational genetic therapy targeted to correcting the underlying molecular defect, altering the natural history of melanoma development may be possible.
Get full access to this article
View all access options for this article.
References
1.
RigelDSKopfAWFriedmanRJ. The rate of malignant melanoma in the US: Are we making an impact?J Am Acad Dermatol1987; 17:1050–1053
2.
WalshPGibbsPGonzalezR. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol2000; 42:480–489
3.
BlissJMFordDSwerdlowAJ. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer1995; 62: 367–376
4.
FountainJWBaleSJHousmanDE. Genetics of melanoma. Cancer Surv1990; 9:645–671
5.
LugerTAScholzenTGrabbeS. The role of alpha melanoctye stimulating hormone in cutaneous biology. J Invest Dermatol Symp Proc1997; 2:87–93
6.
Romero-GrailletCAberdamEClementM. Nitric oxide produced by ultraviolet-irradiated keratinocytes stimulates melanogenesis. J Clin Invest1997; 99:635–642
7.
ChedekelMRSmithSKPostPW. Photodestruction of pheomelanin: Role of oxygen. Proc Natl Acad Sci USA1978; 75:5395–5399
8.
HarsanyiZPPostPWBrinkmanJP. Mutagenicity of melanin from human red hair. Experientia1980; 36:291–292
9.
VincensiMRd'IschiaMNapolitanoA. Phaeomelanin versus eumelanin as a chemical indicator of ultraviolet sensitivity in fair skinned subjects at high risk for melanoma: A pilot study. Melanoma Res1998; 8:53–57
10.
ConeRDLuDKoppulaSA. The melanocortin receptors: Agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res1996; 51:287–317
11.
ValverdePHealyEJacksonI. Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet1995; 11:328–330
12.
SmithRHealyESiddiquiS. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol1998; 111:119–122
13.
FoxNFWyethJRO'GormanLE. Characterization of melanocyte stimulating hormone receptor variants in twins with red hair. Hum Mol Genet1997; 6:1891–1897
14.
HuntGToddCThodyAJ. Unresponsiveness of human epidermal melanocytes to melanocyte-stimulating hormone and its association with red hair. Mol Cell Endocrinol1996; 116:131–136
15.
FrandbergPADoufexisMKapasS. Human pigmentation phenotype: A point mutation generates nonfunctional MSH receptor. Biochem Biophys Res Commun1998; 245:490–492
16.
HealyEFlannaganNRayA. Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair. Lancet2000; 355:1072–1073
17.
ValverdePHealyESikkinkS. The Asp84Glu variant of the melanocortin 1 receptor is associated with melanoma. Hum Mol Genet1996; 5:1663–1666
18.
GruisNAvan der VeldenPASandkuijlLA. Variants of the melanocyte-stimulating hormone receptor gene modify melanoma risk in familial atypical multiple mole-melanoma (FAMM) syndrome families. Melanoma Res1997; 7:S9
19.
PalmerJSDuffyDLBoxNF. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype?Am J Hum Genet2000; 66:176–186
20.
ClarkWHJrReimerRRGreeneMM. Origin of familial malignant melanoma from heritable melanocytic lesions: The B-K mole syndrome. Arch Dermatol1978; 114:732–738
21.
CrutcherWASagebielRW. Prevalence of dysplastic nevi in a community practice. Lancet1984; 322:729
22.
FoulkesWDFlandersTYPollockPM. The CDKN2A (p16) gene and human cancer. Mol Med1997; 3:5–20
23.
LiggettWHJrSidranskyD. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol1998; 16:1197–1206
24.
FountainJWKarayiorgouMErnstoffMS. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA1992; 89:10557–10561
25.
SherrCJRobertsJM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev1999; 13:1501–1512
26.
Cannon-AlbrightLAMeyerLJGoldgarDE. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res1994; 54:6041–6044
27.
WalkerGJHussussianCJFloresJF. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet1995; 4:1845–1852
28.
MonzonJLiuLBrillH. CDKN2A mutations in multiple primary melanomas. N Engl J Med1988; 388:879–887
29.
SerranoMLeeHWChinL. Role of the INK4a locus in tumor suppression and cell mortality. Cell1996; 85:27–37
30.
ChinLPomerantzJPolskyD. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev1997; 11:2822–2834
31.
PiepkornM. The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation. J Am Acad Dermatol2000; 42:741–745
32.
TalveLSaurojaICollanY. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer1997; 74:255–259
33.
WangXQGabrielliBGMilliganA. Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay. Cancer Res1996; 56:2510–2514
34.
SoufirNAvrilMFChompretA. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet1998; 7:209–216
35.
ZuoLWegerJYangQ. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet1996; 12:97–99
36.
PomerantzJSchrieber-AgusNLiegeoisNT. The Ink4a Tumor Suppressor Gene Product, p19ARF, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53. Cell1998; 92:713–723
37.
RoblesMTSSymondsHChenJ. Induction versus progression of brain tumor development: Differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Mol Cell Biol1994; 14:2686–2698
38.
SandigVBrandKHerwigS. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med1997; 3:313–319
39.
PierceAMGiminez—ContiIB. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci USA1998; 95:8858–8863
40.
BalchCMReintgenDSKirkwoodJM. Cancer: Principles and practice of oncology, 5th ed.Philadelphia: Lippincot-Raven, pp 1947–1994
41.
MacKieRMTurnerSHarrisonS. A comparison of the rate of development of melanocytic nevi in infants in Scotland and Australia. Melanoma Res1997; 7:S4
42.
BatailleVSniederHMacGregorAJ. Genetics of risk factors for melanoma: An adult twin study of nevi and freckles. J Natl Cancer Inst2000; 92:457–463
43.
MeyerLJGoldgarDECannon-AlbrightLA. Number, size and histopathology of nevi in Utah kindreds. Cytogenet Cell Genet1992; 59:167–169
MartinNGGreenACWardPJ. Moliness, p16 and melanoma: A twin study. Melanoma Res1997; 7:S26
46.
GruisNASandkuijlLAvan der VeldenPA. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res1995; 5:169–177
47.
PuigSRuizACastelT. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet1997; 101:359–364
48.
HarlandMMeloniRGruisN. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet1997; 6:2061–2067
49.
SanfordKKParshadRPriceFM. Radiation-induced chromatid breaks and DNA repair in blood lymphocytes of patients with dysplastic nevi and/or cutaneous melanoma. J Invest Dermatol1997; 109:546–549
50.
SmithPJGreenMHDevlinDA. Abnormal sensitivity to UV-irradiation in cultured skin fibroblasts from patients with hereditary melanoma and the dysplastic nevus syndrome. Int J Cancer1983; 30:39–45
51.
PereraMRUmKIGreeneMH. Hereditary dysplastic nevus syndrome: Lymphoid cell hypermutability in association with increased melanoma susceptibility. Cancer Res1988; 46:358–369
52.
MoriwakiSITaroneRETuckerMA. Hypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines. Cancer Res1997; 57:4637–4641
53.
BeckerBJospeNGoldsmithLA. Melanocytic nevi in Turner syndrome. Pediatr Dermatol1994; 11:120–124
54.
BoroniGLarizzaDVignattiG. The dermatological spectrum of Turner syndrome. J Eur Acad Dermatol Venereol1994; 3:334–340
55.
ZvulunovAWyattDTLaudPW. Influence of genetic and environmental factors on melanocytic naevi: A lesson from Turner's syndrome. Br J Dermatol1998; 138:993–997
56.
GrobJJGouvernetJAymarD. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer1990; 66:387–395
57.
ZvulonovA. Melanoma in Turner syndrome. Int J Dermatol1995; 34:823
58.
HasleHOlsenJHNielsenJ. Occurrence of cancer in women with Turner syndrome. Br J Cancer1996; 76:11565–11569
59.
RichardMAGrobJJAvrilMF. Delays in diagnosis and melanoma prognosis (II): The role of doctors. Int J Cancer2000; 89:280–285
60.
GreeneMH. Genetics of cutaneous melanoma and nevi. Mayo Clin Proc1997; 72:467–474
61.
KellyJWYeatmanJMRegaliaC. A high incidence of melanoma found in patients with multiple dysplastic nevi by photographic surveillance. Med J Aust1997; 167:191–194
